Results 121 to 130 of about 984,029 (267)

Collective Live-Cell Superresolved Traces Reveal Nonaxonomal Dynamics of Intraflagellar Transport Particles at the Ciliary Base [PDF]

, 2017
Tony Yang, Nguyet Thi, Minh Nguyet Thi Tran, Weng Man Chong, Jung‐Chi Liao   +4 more
openalex   +1 more source

Cell density–dependent nuclear‐cytoplasmic shuttling of SETDB1 integrates with Hippo signaling to regulate YAP1‐mediated transcription

FEBS Letters, EarlyView.
At low cell density, SETDB1 and YAP1 accumulate in the nucleus. As cell density increases, the Hippo pathway is gradually activated, and SETDB1 is associated with increased YAP1 phosphorylation. At high cell density, phosphorylated YAP1 is sequestered in the cytoplasm, while SETDB1 becomes polyubiquitinated and degraded by the ubiquitin–proteasome ...
Jaemin Eom, Jaewoong Jang, Jung Sun Park, Yong‐Kook Kang   +3 more
wiley   +1 more source

Early-onset basal cell carcinoma

The Turkish Journal of Pediatrics, 2013
Basal cell carcinoma (BCC) is a common skin cancer that is responsible for approximately 75% of non-melanoma skin cancers. BCC occurs on sunexposed areas in fair-skinned individuals; frequency increases with age and peaks in the seventh decade of ...
Enver Turan, Nurdan Yurt, Yavuz Yeşilova, Gül Türkçü   +3 more
doaj  

Inhibiting stearoyl‐CoA desaturase suppresses bone metastatic prostate cancer by modulating cellular stress, mTOR signaling, and DNA damage response

FEBS Letters, EarlyView.
Bone metastasis in prostate cancer (PCa) patients is a clinical hurdle due to the poor understanding of the supportive bone microenvironment. Here, we identify stearoyl‐CoA desaturase (SCD) as a tumor‐promoting enzyme and potential therapeutic target in bone metastatic PCa.
Alexis Wilson, Mackenzie K Herroon, Shane Mecca, Laimar C Garmo, Jacob Lindquist, Shrila Rajendran, Steve M. Patrick, Izabela Podgorski   +7 more
wiley   +1 more source

Vismodegib and orbital excision for treating locally advanced basal cell carcinoma

, 2018
Daniel T. Hogarty, Nicholas Dewhurst, Benjamin Burt   +2 more
openalex   +2 more sources

Optimum Load Of a Proton Exchange Membrane Fuel Cells Based on Hydrogen Flow Control

, 2023
Triyanto Pangaribowo, Wahyu Mulyo Utomo, Deni Shidqi Khaerudini, Kurniawan Kurniawan, Afarulrazi Abu Bakar, Imam Sutrisno, Monika Retno Gunarti   +6 more
openalex   +1 more source

Knowledge graph-based recommendation framework identifies drivers of resistance in EGFR mutant non-small cell lung cancer [PDF]

, 2022
Anna Gogleva, Dimitris Polychronopoulos, Matthias Pfeifer, Vladimir Poroshin, M. Ughetto, Matthew J. Martin, Hannah Thorpe, Aurélie Bornot, Paul D. Smith, Ben Sidders, Jonathan R. Dry, Miika Ahdesmäki, Ultan McDermott, Eliseo Papa, Krishna C. Bulusu   +14 more
openalex   +1 more source

β‐TrCP overexpression enhances cisplatin sensitivity by depleting BRCA1

Molecular Oncology, EarlyView.
Low levels of β‐TrCP (Panel A) allow the accumulation of BRCA1 and CtIP, which facilitate the repair of cisplatin‐induced DNA damage via homologous recombination (HR) and promote tumor cell survival. In contrast, high β‐TrCP expression (Panel B) leads to BRCA1 and CtIP degradation, impairing HR repair, resulting in persistent DNA damage and apoptosis ...
Rocío Jiménez‐Guerrero, Alejandro Belmonte‐Fernández, Mónica González‐Moreno, Laura Rodríguez‐Cordero, Begoña Pérez‐Valderrama, Joaquín Herrero‐Ruíz, Francisco Romero, Carmen Sáez, Miguel Á. Japón   +8 more
wiley   +1 more source

Nicotinamide N‐methyltransferase promotes drug resistance in lung cancer, as revealed by nascent proteomic profiling

Molecular Oncology, EarlyView.
AZD9291 has shown promise in targeted cancer therapy but is limited by resistance. In this study, we employed metabolic labeling and LC–MS/MS to profile time‐resolved nascent protein perturbations, allowing dynamic tracking of drug‐responsive proteins. We demonstrated that increased NNMT expression is associated with drug resistance, highlighting NNMT ...
Zhanwu Hou, Zhen Wang, Fei Yang, Xiao Han, Lei Li, Huadong Liu   +5 more
wiley   +1 more source

PARP inhibitors elicit distinct transcriptional programs in homologous recombination competent castration‐resistant prostate cancer

Molecular Oncology, EarlyView.
PARP inhibitors are used to treat a small subset of prostate cancer patients. These studies reveal that PARP1 activity and expression are different between European American and African American prostate cancer tissue samples. Additionally, different PARP inhibitors cause unique and overlapping transcriptional changes, notably, p53 pathway upregulation.
Moriah L. Cunningham, Jasibel Vasquez‐Gonzalez, Samantha M. Barnada, Salome Tchotorlishvili, Latese Jones, Ryan Maguire, Genevieve Lewis, Kinza Rizwan, Jenny Deng, Salma Koachar, Drithi Patel, Hailey Shankle, Tessa Mulders, Namra Ajmal, Charalambos Solomides, Emad S. Alnemri, Teresa F. Alnemri, Ayesha A. Shafi, Leonard G. Gomella, Wm Kevin Kelly, Steven B. McMahon, Matthew J. Schiewer   +21 more
wiley   +1 more source